Bedford, MA (October 2016) – First Light Biosciences, a developer of breakthrough automated diagnostic products for rapid, sensitive and cost-effective detection of Healthcare Associated Infections (HAI) today announced their participation in a BBC interview. Speaking to the BBC, Don Straus, CEO of First Light Biosciences, discussed the challenges currently faced by hospitals as it relates to antibiotic resistance and the development going on at First Light Biosciences to combat the challenge.
The BBC recording can be found here. Don Straus’ portion of the interview begins at the 5:20 mark.
About First Light Biosciences
Based in Bedford, Massachusetts, First Light Biosciences is developing breakthrough automated medical diagnostic products for rapid, sensitive, and cost-effective detection of Healthcare Associated Infections (HAI). The products address the need for cost-effective and accurate diagnostics to meet the explosive growth in testing. New testing is being driven by clinical studies showing that testing for the infectious agents can help to dramatically lower the rate of hospital infections. Based on its proprietary MultiPath™ detection technology, First Light’s products combine the performance of the most advanced commercial laboratory tests with affordability and ease-of-use. To learn more, visit www.firstlightibio.com